Presenting at ECTRIMS 2024, researchers evaluated the long-term disability in children with MS who received monoclonal antibodies at different stages of life.

Presenting at ECTRIMS 2024, researchers prospectively examined remyelination of MS lesions following a 2-year treatment period with cladribine, as well as the effect of controlled inflammatory activity on remyelination capacity.

Researchers conducted a nationwide study to determine the risk for severe relapse after at least 1 dose of COVID-19 vaccination among patients with multiple sclerosis.

Presence of three or more comorbidities, two or more cardiometabolic comorbidities, one psychiatric disorder linked to evidence of disease activity.

Researchers conducted a cross-sectional survey to investigate priorities for access to care and affordability of care by patients with multiple sclerosis living in the US.

Researchers conducted a case-control study to investigate the relationship between socioeconomic status and risk for pediatric-onset multiple sclerosis.

Researchers aimed to determine if ofatumumab and teriflunomide are similarly efficacious and safe in relapsing multiple sclerosis by race/ethnicity subgroup.

Researchers sought to assess the capacity for age-adjusted z scores of OCT-derived measures to determine future disease activity and disability in multiple sclerosis.

Researchers assessed the long-term effects of ofatumumab on clinical outcomes in patients of with relapsing multiple sclerosis of different racial and ethnic backgrounds.

Researchers sought to assess whether an alternative premedication may decrease infusion-related symptoms and ease administration in patients with multiple sclerosis who receive treatment with ocrelizumab.

Researchers sought to assess the pregnancy and infant outcomes among women with MS on ocrelizumab before or during pregnancy and/or breastfeeding.

In a population-based study, researchers assessed the association between time spent in Canada and the risk for multiple sclerosis in Canadian immigrants.

In an observational cohort study, researchers assessed whether discontinuation vs continuation of high-efficacy therapies in older patients with nonactive MS is associated with a higher risk for relapse.

In a longitudinal analysis, researchers evaluated how high-efficacy therapies impact transitions across 5 disability states in patients with pediatric-onset multiple sclerosis.

Researchers conducted an open-label extension study to assess the efficacy of first-line ofatumumab treatment up to 6 years in patients with relapsing multiple sclerosis.

In a meta-analysis, researchers evaluated the incidence and determinants of seizures in patients with multiple sclerosis.

In a retrospective analysis, researchers evaluated the effect of DMT discontinuation on risk for disease activity in MS.

In a prospective, open-label, single-arm, phase 4 trial, researchers evaluated the safety and efficacy of ocrelizumab in Black and Hispanic patients with relapsing MS.

Researchers conducted a cohort study to assess the safety and GLP-1 therapy among patients with multiple sclerosis and obesity.

Researchers assessed the use of highly effective therapies as index treatments for pediatric-onset MS disease activity.

In an ad hoc interim analysis presented at ACTRIMS Forum 2024, researchers described changes in reported outcomes by patients with relapsing MS after 1 year on ozanimod.

In a study presented at ACTRIMS Forum 2024, researchers reported on the latest cumulative pregnancy outcomes data in women with relapsing MS on ofatumumab during or in the 6 months prior to pregnancy.

In a study presented at ACTRIMS Forum 2024, researchers reported whether patients with RMS who received ofatumumab 20 mg every 4 weeks could mount a humoral immune response to the 2020-2021, 2021-2022, or 2022-2023 inactivated influenza vaccine.

In a study presented at ACTRIMS Forum 2024, researchers compared the risk for severe infections between patients with MS treated with diroximel fumarate vs anti-CD20s.

Researchers evaluated differences in relapse rates and Expanded Disability Status Scale scores in patients with multiple sclerosis who were and were not infected with COVID-19.

Researchers sought to assess whether the Dietary Inflammatory Index (DII®) is associated with depression, anxiety, and fatigue in patients with MS.

In a cross-sectional cohort study, researchers assessed the gynecologic care of women with multiple sclerosis of reproductive age.

In a cross-sectional study, researchers examined differences in walking and physical performance in Black and White patients with MS and healthy individuals.

Researchers sought to assess the effect of breastfeeding on the risk of developing familial MS in patients with positive MS history.

In a nested case-control study, researchers assessed the effect of smoking on the risk of developing multiple sclerosis in Black and White US military personnel.